Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D
- 23 May 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , 180-198
Abstract
Context: Metabolic dysfunction–associated steatotic liver disease is prevalent in type 2 diabetes (T2D) and exacerbates hyperglycemia, but its impact on postprandial glucagon suppression remains unclear. Objective: To investigate the association between hepatic steatosis and impaired glucagon suppression during oral glucose tolerance tests (OGTTs), and to evaluate the mediating role of glucagon dysregulation in linking liver fat to glycemic control. Methods: In this cross-sectional study, 604 patients with T2D underwent liver fat quantification via the FibroScan Pro controlled attenuation parameter (CAP) and liver ultrasound. Postprandial glucagon suppression was assessed during 180-minute OGTTs (0, 30, 60, 120, 180 minutes), with continuous glucose monitoring (CGM) in 287 participants. Glucagon suppression was calculated for early (0-30 minutes), late (30-180 minutes), and overall (0-180 minutes) phases. Multivariable regression and mediation analyses tested associations between CAP, glucagon dynamics, and CGM-derived glycemic profiles. Results: Patients with T2D with MASLD (CAP ≥238 dB/m, n = 414) exhibited significantly impaired glucagon suppression compared to non-MASLD controls (n = 190) across all phases (all P < .05). Each 1-SD CAP increase independently predicted attenuated dose-dependent suppression in all phases (standardized β = 0.183–0.303, P < .001). Males showed greater suppression impairment than females and stronger CAP-associated dysregulation. Mediation analysis revealed that glucagon suppression mediated 14.9% to 33.9% of the adverse effects of liver fat on hyperglycemia. Conclusion: Liver fat accumulation in T2D is strongly associated with defective postprandial glucagon suppression, particularly in males, which mediates nearly one-third of its detrimental impact on glycemic control. Targeting hepatic steatosis and glucagon signaling may offer novel therapeutic strategies for T2D management.Keywords
Funding Information
- Noncommunicable Chronic Diseases-National Science and Technology (2023ZD0507400)
- Noncommunicable Chronic Diseases-National Science and Technology (2023ZD0507402)
- National Natural Science Foundation of China (82230028)
- National Natural Science Foundation of China (82170837)
- National Natural Science Foundation of China (81900708)
- Jiangsu Provincial Medical Key Discipline (ZDXK202202)
This publication has 75 references indexed in Scilit:
- 100 years of glucagon and 100 moreDiabetologia, 2023
- The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levelsDiabetologia, 2020
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 DiabetesDiabetes Therapy, 2012
- Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitusDiabetologia, 2007
- Glucagon secretion in relation to insulin sensitivity in healthy subjectsDiabetologia, 2005
- Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemiaDiabetologia, 2003
- Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian womenDiabetologia, 2000
- Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patientsDiabetologia, 1993
- Ovarian-adrenal interactions in regulation of endocrine pancreatic function in the ratDiabetologia, 1983